# Golcadomide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/golcadomide

> The next catalyst for golcadomide, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Aug to Nov 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | golcadomide |
| Codes | BMS-986369, CC-99282 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Large B-cell Lymphoma](https://sec-api.dev/indications/large-b-cell-lymphoma), [Follicular Lymphoma](https://sec-api.dev/indications/follicular-lymphoma), Lymphoma, Follicular |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 19, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Lymphoma, Follicular.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06425302 (A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT06425302

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Large B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT06356129

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Large B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT06356129

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06911502 (A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-24 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT06911502

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06911502 (A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-24 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT06911502

## Same indication

- [AZD0486](https://sec-api.dev/pdufa/azd0486) (AZN)
- [Cemacabtagene ansegedleucel](https://sec-api.dev/pdufa/cemacabtagene-ansegedleucel) (ALLO)
- [Rondecabtagene autoleucel](https://sec-api.dev/pdufa/rondecabtagene-autoleucel) (LYEL)
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig) (AZN)

Calendar months: [August 2027](https://sec-api.dev/fda-calendar/2027-08), [April 2028](https://sec-api.dev/fda-calendar/2028-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/golcadomide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Golcadomide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/golcadomide

```bibtex
@misc{secapidev_pdufa_golcadomide_20261116,
  title        = {Golcadomide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/golcadomide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_golcadomide_20261116","title":"Golcadomide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/golcadomide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
